Kashiv deal financing advances with $350 million of new term debt

The market already knew the Kashiv acquisition was coming. Amneal announced the transaction on April 21, 2026, with $375 million of cash, $375 million of equity, and up to $350 million of contingent payments; the acquisition was expected to close in the second half of 2026 and was explicitly not subject to a financing condition.

The new information is the funding mechanism: $350 million of incremental term debt. Bank of America committed to provide the full amount, with proceeds dedicated primarily to financing the Kashiv purchase and any excess available for general corporate purposes (Article II, Sections 2.1-2.2). The debt is added to the existing Amendment No. 3 term loans, carries the same maturity, interest and prepayment terms, and is secured by the existing collateral package (Article II, Section 2.3; Article VI, Sections 6.1 and 6.5).

This advances closing readiness but increases financial leverage. The loan becomes effective only when the acquisition has closed or is closing concurrently, and the agreement sets a final effectiveness deadline of January 12, 2027 (Conditions to Effectiveness, Sections 4.1(j)-(k)). The filing does not disclose the resulting pro forma leverage, interest rate spread, or total debt balance, so the incremental burden cannot be quantified from this document alone.

Net read: strategically constructive, financially offsetting, and not a clear surprise versus expectations. The agreement removes a meaningful financing execution hurdle for an already-announced acquisition, but it does so by adding secured debt rather than changing the deal economics or improving the purchase price. Because the acquisition and its substantial cash requirement were already public, this is best read as confirmation of transaction funding—not a clean positive surprise.